|
Science
Behind the Cure for Common Cold |
The following materials are provided for
interested laymen and professionals wanting solid, factual information about
the powerful, and beneficial effects of Zn2+ ions in
treating common colds and other important illnesses. There are many internal
and external links with links to movies of rhinoviruses from 3 different
perspectives, and much more vital and accurate information than all but the
most ardent professional can tolerate. But! The data are provided in easy to
chew, byte size bits.
- NEW! "Zinc Lozenges: Cold Cure or
Candy? Solution Chemistry Determinations" published in the
February issue of Bioscience
Reports. This is the latest peer reviewed article by George
Eby. It shows that the relationship
of daily iZn [total daily positively charged zinc ions (in mg) at
physiologic pH] from zinc lozenges in clinical trials is directly
correlated with both median reduction in duration of common colds in days,
and mean reduction of duration of common colds in days.
Legend: ZG = zinc gluconate, ZGG = zinc gluconate-glycinate, ZA = zinc acetate,
ZA-SOP = zinc acetate-sterate-oleate-palmitate, ZG-C = zinc gluconate-citrate.
- NEW! Zinc Lozenges: A Comparision of many
different commercial zinc lozenges for efficacy.
- NEW! From the same report, as an extension: Solution chemistry
determinations for: zinc acetate, zinc gluconate, zinc gluconate
glycine and zinc citrate.
- "Does Zinc Really
Cure the Common Cold? is quite brief, and is an excellent place to
begin one's research in order to understand why only a very few zinc
compounds out of many are effective against colds when incorporated
into lozenges.
- Prasad AS, Beck
FW, Bao B, Snell D, Fitzgerald JT. Duration and Severity of Symptoms and
Levels of Plasma Interleukin-1 Receptor Antagonist, Soluble Tumor Necrosis
Factor Receptor, and Adhesion Molecules in Patients with Common Cold
Treated with Zinc Acetate. J Infect
Dis. 2008;197:795-802
- Duration
of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated
with Zinc Acetate, Ananda S. Prasad, MD, PhD, et. al., Annals of
Internal Medicine, August 15, 2000, Vol. 133, Pages 245-252. PDF Full Text Version This is a
report of the efficacy of Eby's george-eby-research zinc acetate lozenge
formula using 12.8 mg of zinc per lozenge.
- Petrus, Ed. "Randomized,
Double-Matched, Placebo-Controlled, Clinical Study of the Effectiveness of
Zinc Acetate Lozenges on Common Cold Symptoms in Allergy-Tested
Subjects", Current Therapeutic Research, vol 59, no 9,
pages 595-607, September 1998. This is a report of the efficacy of
Eby's george-eby-research zinc acetate lozenge formula using 9.0 mg of
zinc per lozenge.
- This 1988 article is the first to expose the enormous differences
in chemistry between the lozenges used in the 1984 Eby et al. report and
several other negative reports by authorities in the field: Eby,
G. A., Stability Constants of Zinc Complexes Affect Common Cold Treatment
Results, Antimicrobial Agents and Chemotherapy 1988;32:606-607.
- Why Zn2+ ions? In 1976 Korant
and Butterworth found that Zn2+ ions
from zinc chloride and zinc acetate complexes with rhinovirus coat
proteins and alters them so that they cannot function as substrates for
proteases or as reactants in the assembly of the virus particles.
- In 1991 evidence that zinc (Zn2+) ions are an effective inhibitor of protease
C3, important due to its rate limiting effect on rhinovirus replication,
can be inferred from its action on the poliovirus
protease C3.
- Poliovirus and rhinovirus are members of the picornavirus
RNA virus family.
- 2001
UPDATE of "Chapter 2:
In Vitro Effects of Zn2+
ions" of my 1994 Handbook for Curing the Common Cold. Much
broader in vitro information including the action of zinc in mediators of
common cold symptoms is now available.
- The first peer reviewed report on the use of Zn2+ ions from throat lozenges to shorten the
duration and severity of common colds: Eby,
G. A., Davis D. R., Halcomb W. W., Reduction in Duration of Common Colds
by Zinc Gluconate Lozenges in a Double Blind Study. Antimicrobial
Agents and Chemotherapy 1984;25:20-24.
- The first
and only study to replicate my original findings using live
rhinovirus. The lozenges contained zinc gluconate, fructose and
hydroxypropyl methylcellulose and were tested by the British Medical
Council in 1987 and are reviewed in my handbook in Chapter 4.a.2..
The full article is presented here.
- Handbook for Curing the
Common Cold -- the Zinc Lozenge Story Library of Congress Catalog Card
Number: 93-090841, ISBN 0-9638967-0-9. This is a 100+ page book with 27
technical figures, 16 tables of data and complex mathematical expressions.
The 1994 handbook is vital for the true common cold researcher. The price
of the physical book is $299.95, as it has become a historical medical
collector's item. But the virtual information is here -- free! Just for
you! And, from the table of contents, list of figures, and list of tables,
there are direct internal links to any topic you might desire.
- Taken from my 1994 handbook, my next peer reviewed article was
published in the Journal of Pharmacy Technology in the May/June,
1995, issue. It is entitled Linearity
in Dose-Response from Zinc Lozenges in Treatment of Common Colds. It
is primarily for researchers wishing to quickly and conveniently: (a)
obtain a strong scientific and technical understanding of the in vitro
effects of Zn2+ ions, (b) understand the solution chemistry,
biochemistry, and biophysics related to Zn2+ ions and common cold research, (c) review analyses
of all pre-1996 published zinc lozenge for common cold reports, and (d) be
introduced to the exciting technology behind zinc acetate lozenges.
Unfortunately, this article was published in a journal that was not
indexed by Index Medicus.
- "The Zinc
Lozenge and Common Cold Story", in the internationally
contributed, state-of-the-art, 4 volume set -- Metal-Ligand Interactions
in Biological Fluids: Bioinorganic Medicine, Volume 2, pages 1182-1190, Marcel
Dekker, Inc., New York, 1995. The editor (my mentor in solution
chemistry), Guy Berthon, PhD, is Director of Research for Unit 305 (Equipe
"Bioréaciifs : Spéciation et Biodisponibilité"), at the Institut
National de la Santé et de la Recherché Médicale (INSERM), in Toulouse,
France, a part of the Centre National de la Recherché Scientifque (CNRS),
Paris, France. Dr. Berthon freely assisted in this article by computing
zinc speciation by pH for several critical zinc compounds in solution.
- The most concise article on zinc lozenges and colds is the invited
opinion Zinc lozenges as cure
for common colds, Annals of Pharmacotherapy 1996:30;1336-1338.
It is a 1770 word summary of the whole zinc lozenge for common colds
enchilada -- and if you read the last three paragraphs carefully -- they
will open a 21st century research gateway to cures for otherwise lethal
viral infections, tissue necroses, anaphylactic shock, respiratory
distress, and so forth. PubMed
- This peer reviewed article is indexed in Index Medicus Zinc
Ion Availability: The Determinant of Efficacy in Zinc Lozenge Treatment of
Common Colds, Journal of Antimicrobial Chemotherapy
1997:40;483-493. The full text
of the article is presented here .
- Zinc ion availability and
the common cold This is the published abstract of my oral presentation
at the Vth Conference of
The International Society for Trace Element Research in Humans (ISTERH) <<
New Aspects of Trace Element Research >> held in Lyon,
France from 26th September to 1st October 1998.
- Cold-Eeze(r) Related Annals
of Internal Medicine (AIM) articles The debate intensifies in the
January 1, 1998 issue of AIM in the letters to the editor column. The
public is first informed about the FDA's chief common cold consultant's
vested financial interests in his own patented work.